TCBP vs. ACORQ, SCNI, ACOR, SQZ, GMDAQ, GMDA, WINT, ELOX, ALBT, and KRBP
Should you be buying TC Biopharm stock or one of its competitors? The main competitors of TC Biopharm include Acorda Therapeutics (ACORQ), Scinai Immunotherapeutics (SCNI), Acorda Therapeutics (ACOR), SQZ Biotechnologies (SQZ), Gamida Cell (GMDAQ), Gamida Cell (GMDA), Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), Avalon GloboCare (ALBT), and Kiromic BioPharma (KRBP). These companies are all part of the "biological products, except diagnostic" industry.
Acorda Therapeutics (NASDAQ:ACORQ) and TC Biopharm (NASDAQ:TCBP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, community ranking, profitability, dividends, earnings and media sentiment.
TC Biopharm has lower revenue, but higher earnings than Acorda Therapeutics.
TC Biopharm has a net margin of 0.00% compared to TC Biopharm's net margin of -214.95%. Acorda Therapeutics' return on equity of 0.00% beat TC Biopharm's return on equity.
Acorda Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, TC Biopharm has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500.
12.7% of Acorda Therapeutics shares are held by institutional investors. Comparatively, 16.3% of TC Biopharm shares are held by institutional investors. 2.6% of Acorda Therapeutics shares are held by insiders. Comparatively, 0.1% of TC Biopharm shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
TC Biopharm received 1 more outperform votes than Acorda Therapeutics when rated by MarketBeat users.
In the previous week, TC Biopharm had 6 more articles in the media than Acorda Therapeutics. MarketBeat recorded 6 mentions for TC Biopharm and 0 mentions for Acorda Therapeutics. Acorda Therapeutics' average media sentiment score of 0.28 beat TC Biopharm's score of 0.00 indicating that TC Biopharm is being referred to more favorably in the news media.
Summary
TC Biopharm beats Acorda Therapeutics on 9 of the 12 factors compared between the two stocks.
Get TC Biopharm News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCBP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TC Biopharm Competitors List
Related Companies and Tools
